Mankind Pharma Limited — Q3 FY26 earnings call

Call held 3 Feb 2026

Management summary

Mankind Pharma delivered a robust Q3 FY26, with strong revenue growth across domestic and international segments, driven by chronic therapies and the BSV portfolio. Despite a dip in adjusted EBITDA margin due to R&D and employee costs, the company maintained healthy profitability and significantly improved its net debt position. Management highlighted ongoing strategic transformations and expressed confidence in future growth, particularly in chronic and OTC segments, while addressing challenges in acute and anti-infective categories.

Highlights

  • Q3 overall revenue increased by 11.5% YoY to INR3,567 crores, and 9M revenue grew 18.7% YoY to INR10,835 crores.

  • Q3 adjusted EBITDA margin was 25.9%, with 9M adjusted EBITDA margin at 24.9%.

  • Domestic business grew 11.1% YoY in Q3, with organic growth (excluding OTC) at 9.1%.

  • Chronic therapies demonstrated strong growth of 16.7% in cardio and 14.4% in antidiabetes in Q3.

  • Mankind's overall PCPM improved to INR7.2 lakhs as on December 31, 2025, from INR6.5 lakhs as of March 31, 2025.

  • Net debt reduced to INR4,294 crores as of December 31, 2025, resulting in a net debt to adjusted EBITDA ratio of 1.3x (trailing 12 months), an improvement from 1.4x on September 30, 2025.

Concerns

  • Q3 adjusted EBITDA margin declined by 170 bps YoY to 25.9% (from 27.6% in Q3 FY25) due to increased R&D cost (70 bps) and higher employee costs.

  • Q3 reported EBITDA margin was 22.9%, 300 bps lower than adjusted EBITDA margin, due to exceptional items including New Labour Code adoption, stamp duty on BSV slump sale, and impairment of noncurrent surplus assets.

  • Acute segments remained softer in Q3, with anti-infectives segment performance being relatively muted.

  • OTC business growth of 5.2% YoY in Q3 was muted due to a high base effect (30% growth last year) and prior quarter impacts from monsoons and GST 2.0.

Key financials

  1. Revenue ₹3,567 Cr +11.5%YoY
  2. Adjusted EBITDA Margin 25.9%
  3. PAT ₹414 Cr +9.5%YoY
  4. Diluted EPS ₹9.9
  5. Gross Margin 72.6%
  6. R&D Expenses ₹102 Cr

What they filed

Q1 FY27: revenue up 12.9%, net profit up 29.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue3,061 3,199 3,079 3,570 3,697 +21%3,567 +12%3,443 +12%4,031 +13%
EBITDA847 816 683 847 921 +9%919 +13%930 +36%1,056 +25%
Net profit659 385 425 445 520 −21%414 +8%559 +32%574 +29%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Domestic Business
    11.1% Q3 Revenue Growth9.1% Q3 Organic Growth (ex-OTC)₹9,331 Cr 9M Revenue8.2% 9M Organic Growth (ex-OTC)
  • International Business
    ₹521 Cr Q3 Export Revenue₹1,503 Cr 9M Exports
  • OTC Business
    5.2% Q3 Revenue Growth5.6% 9M Revenue Growth
  • Chronic Therapies
    16.7% Q3 Growth (Cardio)14.4% Q3 Growth (Antidiabetes)36.7% 9M Contribution
  • BSV Business
    20% Q3 Growth₹464 Cr Q3 Total Revenue

Capital allocation

high confidence
  • Capex 4.5 %
    Our capex spend for 9 months FY'26 was INR473 crores, which is 4.4% of total revenue and the same is in line with our guidance of 4% to 5% of revenue.
  • Debt Net ₹4,294 Cr · 1.3× EBITDA
    • Repayment Repayment of last tranche of commercial papers ₹1,500 Cr
    In line with our prudent financial strategy, we continue to strengthen our balance sheet and have reduced our net debt to INR4,294 crores as of 31st December 2025, resulting in the net debt to adjusted EBITDA ratio of 1.3x in Q3 '26 on a trailing 12 months basis, which has improved as compared to net debt to adjusted EBITDA ratio of 1.4x as on 30th September 2025.
  • M&A BSV branded generic business Acquisition · Integrated

    Strengthening portfolio and market presence

    Full quarter impact of depreciation and amortization related to BSV assets. Impairment of INR13 crores related to BSV's Hyderabad facility (surplus land).

    As you are aware that the BSV acquisition got completed in Q3 '25 last year, therefore, this quarter will have comparative figures, including BSV, however, the same is on a partial basis as BSV was consolidated for 69 days in Q3 '25 last year as compared to full quarter in Q3 '26. ... Okay, that's a good question, Kunal. So this was a land which was there in the BSV books, okay? And since we are building up the facility at Vadodara. So therefore, this particular piece of land has been classified as a surplus land. So therefore, we are in the process of returning it back to the authorities, this land.

Guidance & targets

Profitability

  • R&D Spend as % of Sales Profitability · full year FY26 · High confidence 2.5% to 3%
    The R&D expense for Q3 '26 remains within the range of 2.5% to 3% of our guidance for the full year FY26.

    — Ashutosh Dhawan

  • Adjusted EBITDA Margin Profitability · 9 months FY26 · Medium confidence closer to lower end of guidance
    Accordingly, the adjusted EBITDA margin for 9 months '26 is 24.9%, which is closer to the lower end of our EBITDA guidance.

    — Ashutosh Dhawan

Capex

  • Capex as % of Revenue Capex · FY26 · High confidence 4% to 5%
    Our capex spend for 9 months FY'26 was INR473 crores, which is 4.4% of total revenue and the same is in line with our guidance of 4% to 5% of revenue.

    — Ashutosh Dhawan

Product Launch

  • GLP-1 Launch Product Launch · March end · High confidence Day 1 launch around March end
    So it's a currently innovator market, and we are on track for a day 1 launch. It would be around March, somewhere around March end. So we are on track, and we expect to be a participant in the launch in day 1.

    — Prakash Agarwal

Growth

  • OTC Business Growth Growth · next year · Medium confidence good double-digit growth
    And we hope that going forward next year, good double-digit growth would be there.

    — Rajeev Juneja

  • IPM Outperformance Growth · going forward · Medium confidence outperform IPM
    So this will also eventually come back. And that's why we have full confidence that we'll be able to outperform IPM going forward.

    — Prakash Agarwal

International Business

  • ROW Commercialization International Business · 2028-2029 · Medium confidence commercialization will happen after a couple of years
    And in ROW, we are in the process of sending the dossier to different countries, the commercialization will happen after a couple of years, maybe 2028-2029.

    — Sheetal Arora

What to watch in Q4 FY26

IPM Outperformance Recovery

next quarter
Current Lagging IPM growth for last 5 months
Target Return to 1.2x-1.3x IPM growth

Why it matters

This is a key historical strength of Mankind Pharma, and its recovery is crucial for overall growth trajectory.

How should we expect them recovering back to the normal 1.2x, 1.3x IPM growth, which traditionally Mankind was delivering?

Risks & concerns

  • Impact of cultural integration challenges from new hires

    high

    Hiring 15-20% new field force and leadership led to overestimation of cultural integration, causing insecurity, attrition, and impacting overall team energy and performance.

    Management acknowledged

  • Muted growth in acute segments and anti-infectives

    medium

    Acute segments remained softer in Q3, with anti-infectives performance muted due to its relationship-driven nature and 3-5 day prescription cycles.

    Management acknowledged

  • Decline in adjusted EBITDA margin

    medium

    Adjusted EBITDA margin declined by 170 bps in Q3 due to increased R&D costs and higher employee expenses.

    Management acknowledged

  • OTC primary sales not reflecting strong secondary sales

    medium

    The gap was due to strategic decisions to reduce stockists and stop 'cash and carry' business to maintain market hygiene, despite strong e-commerce and modern trade growth.

    Analyst explained

  • Lag in net debt reduction despite repayments

    low

    Despite INR1,500 crores of commercial paper repayment, net debt reduction was slower due to the 6-monthly repayment structure, creating a time lag.

    Analyst explained

Q&A highlights

5 direct
Impact of new field force and culture on growth Direct
So the point basically is what, I mean, you're supposed to understand, we have gone for a major kind of a transformation in Mankind, the last, I'll say, 12 to 15 months' time. 2-3 things have happened. Try to understand. One basically is what we started taking a transformation in the form of hiring of approximately 15%-20% field force, reps and managers, leaders as well and then hiring people. In this process, what basically happened, we overestimated our power of executing and making sure that the new people those who join Mankind, understand the culture of Mankind. We overestimated this and we did not understand properly and deeply. I should really confess the problems. Whenever any kind of -- happens and people are being asked that to leave some kind of insecurity creeps in people's mind.

Management candidly explained that the recent growth slowdown was due to internal cultural and integration challenges from hiring a large new field force, leading to insecurity and attrition, rather than external market factors.

Asked by Tushar Manudhane

Sustainability of strong CFO to EBITDA ratio Partial
Yes. So historically, if you see, our CFO to EBITDA ratio has been in the range of 75%-odd or so. In this particular quarter, it is high because of -- one, is that we have been able to optimize on the working capital. So on a year-on-year basis so that has released. Second factor is because we were able to realize some of the government receivables. So because of that also, the cash flow has improved. And if you look at the tax element also, there is a drop in the value term. So these are the 3 factors because of which you see a spike of 25% increase in the CFO to EBITDA ratio. But having said that, it will taper down in the near quarters.

Analyst questioned the sustainability of the very high CFO to EBITDA ratio, and management attributed it to one-time factors like working capital optimization and government receivable realization, indicating it will normalize.

Asked by Tushar Manudhane

Net debt not reflecting commercial paper repayment Partial
So see, net debt is okay because the debt has to be realized over a period because how the debt was structured was that the repayments were coming on a 6 monthly basis. So that is why the net debt is improving, but the overall debt is not, because there is a time gap of 6 months. That's why there is a lag in that.

Analyst observed a discrepancy between significant CP repayment and net debt reduction, which management explained by the 6-monthly repayment structure causing a time lag.

Asked by Chintan Sheth

Gap between OTC primary and secondary sales growth Direct
See, if you just look at our OTC side, the second quarter was approximately minus growth because of this GST and all other things. On the second side, this third quarter. Our growth in e-commerce business is upward of 30%, 40%. In modern trade is upward of 30%, 40%. And at some of the places we have put brakes. And that basically is the reason the growth has not come. There's some business called cash and carry and in that business, what happens, people those who buy instead of selling in the, I'll say, the consumer, they were selling to our own customers. So that basically was creating a kind of rate cuts in the market. That we just taken a, I mean, hard stance on that without taking any other thing in mind.

Management clarified that the divergence between strong secondary sales and lower primary sales in OTC was due to strategic decisions like reducing stockists and stopping 'cash and carry' business to maintain hygiene and prevent rate cuts, despite strong e-commerce and modern trade growth.

Asked by Kunal Dhamesha

Impairment of BSV's Hyderabad facility Direct
Okay, that's a good question, Kunal. So this was a land which was there in the BSV books, okay? And since we are building up the facility at Vadodara. So therefore, this particular piece of land has been classified as a surplus land. So therefore, we are in the process of returning it back to the authorities, this land. So in order to monetize this asset and returning it back. So whatever is the difference between the realizable value and the book value that has been recorded as an impairment cost for this.

Analyst sought clarification on the INR13 crore impairment, which management explained was due to classifying BSV's Hyderabad land as surplus while building a new facility in Vadodara, and the impairment reflects the difference between its realizable and book value.

Asked by Kunal Dhamesha

Timeline for recovery to higher-than-industry growth Direct
Neha, hopefully, I mean, all things are done because see, we have always seen, I mean, more growth than the industry always been like that. We are so used to it that when it did not come, it gave us a surprise and rather shock. And once you basically go to that kind of a phase, you go yourself, check everything, recheck it and you do a bit of micro management as well in a sense that why it is not happening, why these things are there. And once we start seeing it, we found out the reasons and started acting faster. And the answer I gave you in the past as well, I mean, just a few minutes back as well. Then we are seeing the traction is right.

Analyst asked about the timeline for Mankind to return to its historical outperformance, and management expressed confidence that corrective actions have been taken, and traction is now visible, indicating a recovery is underway.

Asked by Neha Manpuria

Impact of 20-25% new field force on company culture and performance Direct
See, it's all a matter of heart only. I mean, for example, if in your office, 20% people are being asked to leave systematically. What kind of energy would be there in total team? Just think about that. That's the right answer. So it's not only numbers that matters. Whatever numbers are left, what kind of a heart and mind they're giving in the work, that also matters a lot. And we are always that kind of organization because where energy is everything. So don't look only numbers, numbers, right? See the force behind numbers. If 80% people start giving 100% kind of their energy, or 110% kind of energy, wonders can be done. If same 80%, only 80% people start giving half of their energy because they're also insecure. They also need some kind of reassurance. So understand that from that perspective, we think from that lines only.

Analyst questioned why a relatively small percentage of new field force (20-25%) had such a significant impact. Management emphasized the psychological impact on the entire team, highlighting that insecurity and lack of reassurance affected overall energy and performance, especially in relationship-driven acute segments.

Asked by Dheeresh

3 min read 6 chapters

Detailed narrative

Q3 and 9M FY26 Financial Performance Overview

Mankind Pharma reported a robust Q3 FY26 with overall revenue increasing by 11.5% year-on-year to INR3,567 crores. For the first nine months of FY26, revenue grew by 18.7% year-on-year to INR10,835 crores. The adjusted EBITDA margin for Q3 stood at 25.9%, while the 9M adjusted EBITDA margin was 24.9%, aligning with the lower end of the company's guidance. PAT for Q3 grew 9.5% year-on-year to INR414 crores, with diluted EPS at INR9.9 per share.

Domestic Business Growth and Segment Performance

The domestic business recorded an 11.1% year-on-year growth in Q3, with organic growth (excluding OTC) at 9.1%. For the nine-month period, domestic revenues increased by 14.8% to INR9,331 crores. Chronic therapies continued their strong momentum, growing 16.7% in cardio and 14.4% in antidiabetes in Q3, and their contribution to 9M revenue increased by 200 bps to 36.7%. The inhaler portfolio grew 30%, and new launches like Vonalong (gastro) and Crenzlo (cardio) achieved 86% and 92% year-on-year growth respectively, securing top ranks in their categories.

OTC and International Business Performance

The OTC business saw a 5.2% year-on-year growth in Q3, with key brands like Gas-O-Fast, Manforce, and Ova News growing 33%, 8%, and 36% respectively in secondary sales. Modern trade and e-commerce channels contributed 13% to OTC sales, growing over 40%. International business exports grew 14% year-on-year to INR521 crores in Q3, and 51% to INR1,503 crores for the nine-month period. The BSV business delivered double-digit growth in Q3, with its 9-month prescription business surpassing FY25 sales.

Margin Dynamics and R&D Investment

Gross margins improved by 170 basis points year-on-year to 72.6% in Q3 FY26. However, the adjusted EBITDA margin saw a 170 bps decline, primarily attributed to a 70 bps increase in R&D costs and higher employee expenses. R&D expenses for Q3 were INR102 crores, representing 2.9% of sales, which is within the full-year guidance of 2.5% to 3%. The reported EBITDA margin was further impacted by 300 bps due to exceptional items, including New Labour Code adoption and impairment of noncurrent surplus assets.

Capital Structure and Debt Management

Mankind Pharma demonstrated prudent financial management, reducing its net debt to INR4,294 crores as of December 31, 2025. This led to an improved net debt to adjusted EBITDA ratio of 1.3x on a trailing 12-month basis, down from 1.4x in the previous quarter. The finance cost decreased to INR157 crores in Q3, driven by the repayment of INR1,500 crores worth of commercial papers in October 2025. The CFO to EBITDA ratio for 9M FY26 significantly improved to 93% from 68% in 9M FY25, aided by working capital optimization and realization of government receivables.

Strategic Transformation and Cultural Integration Challenges

Management acknowledged that a significant transformation over the past 12-15 months, involving hiring 15-20% new field force and leadership, led to initial challenges. Overestimation of cultural integration and subsequent insecurity among employees resulted in attrition and muted growth in certain segments, particularly acute and anti-infectives. However, management asserted that these issues are now understood, corrective actions are in place, and the company is back on track, with improving workforce stability and confidence.

This is an AI-generated summary of a publicly available earnings call transcript.